- Report
- May 2023
- 80 Pages
Germany
From €2509EUR$2,595USD£2,156GBP
- Report
- May 2023
- 80 Pages
France
From €2509EUR$2,595USD£2,156GBP
- Report
- May 2023
- 80 Pages
China
From €2509EUR$2,595USD£2,156GBP
- Report
- May 2023
- 80 Pages
Brazil
From €2509EUR$2,595USD£2,156GBP
- Report
- July 2023
- 132 Pages
Global
From €918EUR$950USD£789GBP
- Report
- February 2024
- 205 Pages
Global
From €3480EUR$3,600USD£2,991GBP
- Report
- February 2024
- 193 Pages
Global
From €3480EUR$3,600USD£2,991GBP
- Report
- December 2021
- 255 Pages
Global
From €5963EUR$6,168USD£5,125GBP
- Report
- October 2023
- 140 Pages
Global
From €2899EUR$2,999USD£2,492GBP
- Book
- December 2021
- 576 Pages
- Book
- September 2021
- 464 Pages
- Book
- July 2015
- 384 Pages
- Book
- April 2022
- 300 Pages
- Book
- August 2020
- 432 Pages
The Pulmonary Drug Delivery market is a subset of the larger Drug Delivery market, which focuses on the delivery of drugs to the lungs. This type of delivery is used to treat a variety of respiratory diseases, such as asthma, COPD, and cystic fibrosis. Pulmonary drug delivery systems are designed to deliver drugs directly to the lungs, allowing for a more targeted and efficient delivery of medication. These systems can be used to deliver both small and large molecules, and can be administered through inhalation, nebulization, or other methods.
The Pulmonary Drug Delivery market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. Show Less Read more